uniQure Stock: Worst Case Scenario Becomes Reality (NASDAQ:QURE)

Company Overview - uniQure's stock experienced a significant decline after the company reported no progress in its Type A meeting with the FDA regarding its AMT-130 treatment for Huntington's disease [1] Investment Strategy - Narweena, an asset management firm, focuses on identifying market dislocations caused by misunderstandings of long-term business prospects, aiming for excess risk-adjusted returns through secular growth opportunities in markets with entry barriers [1] - The firm emphasizes a research process centered on company and industry fundamentals to uncover unique insights, with a high risk appetite and a long-term investment horizon targeting deeply undervalued stocks [1] Market Dynamics - An aging population with low growth and stagnating productivity is expected to create new investment opportunities, contrasting with past trends [1] - Many industries may face stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] - The economy is increasingly influenced by asset-light businesses, leading to a declining need for infrastructure investments, resulting in a limited set of investment opportunities driving up asset prices and compressing risk premia over time [1]